Self Care Forum venous disease fact sheet
A summary of recommendations for advising patients and the public on managing venous disease
HEART UK Managing hyperlipidaemia and COVID-19
A summary of collated current evidence surrounding the safety of lipid-lowering medications in patients who have COVID-19
Stable peripheral arterial disease guideline
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.
Stable coronary artery disease guideline
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
SIGN antithrombotics guideline
A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.
Resource hub
Practical guide to recording ankle brachial pressure index (ABPI)
- Previous
- Next
Educational resources
Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure
This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.
Anticoagulation management for elderly patients with NVAF, CKD and other comorbidities
This promotional webinar was organised and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals only.
Click HERE to view ELIQUIS (apixaban) prescribing information and adverse events reporting
Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK).
432-GB-2200204 May 2022
Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care
This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only.
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021
Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2416 March 2022
Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2415 January 2022